Clinical Significance of Radiation-induced Liver Disease After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2017 Aug 28

PMID 28844122

Citations 20

Authors

Baek Gyu Jun

Young Don Kim

Gab Jin Cheon

Eun Seog Kim

Eunjin Jwa

Sang Gyune Kim

Young Seok Kim

Boo Sung Kim

Soung Won Jeong

Jae Young Jang

Sae Hwan Lee

Hong Soo Kim

Affiliations

Soon will be listed here.

Abstract

Background/aims: The aim of this study was to investigate parameters that predict radiation-induced liver disease (RILD) following stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma (HCC) and to identify the clinical significance of RILD.

Methods: We retrospectively reviewed the medical records of 117 HCC patients who were treated by SBRT from March 2011 to February 2015. RILD was defined as elevated liver transaminases more than five times the upper normal limit or a worsening of Child-Pugh (CP) score by 2 within 3 months after SBRT. All patients were assessed at 1 month and every 3 months after SBRT.

Results: Median follow-up was 22.5 months (range, 3 to 56) after SBRT. RILD was developed in 29 of the 117 patients (24.7%). On univariate analysis, significant predictive factors of RILD were pretreatment CP score (p < 0.001) and normal liver volume (p = 0.002). Multivariate analysis showed that CP score was a significant predictor of RILD (p < 0.001). The incidence of RILD increased above a CP score of 6 remarkably. The rate of recovery from RILD decreased significantly above a CP score of 8. Survival analysis showed that CP score was an independent prognostic factor of overall survival (p = 0.001).

Conclusion: CP score is a significant factor to predict RILD in patients with chronic liver disease. RILD can be tolerated by patients with a CP score ≤ 7. However, careful monitoring of liver function is needed for patients with a CP score 7 after SBRT.

Citing Articles

Radiation hepatitis after postmastectomy radiation therapy for early breast cancer: difficult to differentiate from drug-induced liver injury caused by abemaciclib.

Nakamoto S, Waki T, Mimata A, Tsukioki T, Takahashi Y, Iwatani Y Int Cancer Conf J. 2024; 13(4):471-475.

PMID: 39398903 PMC: 11464992. DOI: 10.1007/s13691-024-00714-1.

Current Insights into Molecular Mechanisms and Potential Biomarkers for Treating Radiation-Induced Liver Damage.

Saha B, Pallatt S, Banerjee A, Banerjee A, Pathak R, Pathak S Cells. 2024; 13(18.

PMID: 39329744 PMC: 11429644. DOI: 10.3390/cells13181560.

Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience.

Park S, Rim C, Yoon W Saudi J Gastroenterol. 2024; 30(6):399-406.

PMID: 39215481 PMC: 11630486. DOI: 10.4103/sjg.sjg_195_24.

Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial.

Lin Y, Wu G, Rao M, Liu Y, Han Y, Zhang J Sci Rep. 2024; 14(1):11486.

PMID: 38769368 PMC: 11106273. DOI: 10.1038/s41598-024-62523-z.

Prognostic analysis of radiation-induced liver damage following carbon-ion radiotherapy for hepatocellular carcinoma.

Hayashi K, Suzuki O, Wakisaka Y, Ichise K, Uchida H, Anzai M Radiat Oncol. 2024; 19(1):51.

PMID: 38649902 PMC: 11034055. DOI: 10.1186/s13014-024-02444-3.

References

Culleton S, Jiang H, Haddad C, Kim J, Brierley J, Brade A . Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014; 111(3):412-7. DOI: 10.1016/j.radonc.2014.05.002. View

Liang S, Zhu X, Xu Z, Zhu J, Zhao J, Lu H . Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006; 65(2):426-34. DOI: 10.1016/j.ijrobp.2005.12.031. View

Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K . Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer. 1991; 68(10):2150-4. DOI: 10.1002/1097-0142(19911115)68:10<2150::aid-cncr2820681011>3.0.co;2-f. View

Dawson L, Normolle D, Balter J, McGinn C, Lawrence T, Ten Haken R . Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002; 53(4):810-21. DOI: 10.1016/s0360-3016(02)02846-8. View

Kim H, Park J, Joo J, Kim H, Woo S, Lee W . Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2013; 28(11):1756-61. DOI: 10.1111/jgh.12310. View

Guha C, Kavanagh B . Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol. 2011; 21(4):256-63. PMC: 3434677. DOI: 10.1016/j.semradonc.2011.05.003. View

Sheu J, Huang G, Chen D, SUNG J, Yang P, Wei T . Small hepatocellular carcinoma: intratumor ethanol treatment using new needle and guidance systems. Radiology. 1987; 163(1):43-8. DOI: 10.1148/radiology.163.1.3029806. View

Cardenes H, Price T, Perkins S, Maluccio M, Kwo P, Breen T . Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010; 12(3):218-25. DOI: 10.1007/s12094-010-0492-x. View

Liang S, Huang X, Zhu X, Zhang W, Cai L, Huang H . Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh Grade A cirrhosis. Radiother Oncol. 2010; 98(2):265-9. DOI: 10.1016/j.radonc.2010.10.014. View

10.

Okajima C, Arii S, Tanaka S, Matsumura S, Ban D, Ochiai T . Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection. Am J Surg. 2014; 209(1):199-205. DOI: 10.1016/j.amjsurg.2014.03.009. View

11.

Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C . The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015; 141(7):1301-9. DOI: 10.1007/s00432-015-1929-y. View

12.

Song J, Son S, Kay C, Jang H . Identification of Biologically Effective Dose-Volumetric Parameters That Predict Radiation-Induced Hepatic Toxicity in Patients Treated With Helical Tomotherapy for Unresectable Locally Advanced Hepatocellular Carcinoma. Medicine (Baltimore). 2015; 94(43):e1904. PMC: 4985424. DOI: 10.1097/MD.0000000000001904. View

13.

Kim T, Kim D, Park J, Kim S, Choi J, Kim H . Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 67(1):225-31. DOI: 10.1016/j.ijrobp.2006.08.015. View

14.

Pan C, Kavanagh B, Dawson L, Li X, Das S, Miften M . Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010; 76(3 Suppl):S94-100. PMC: 4388033. DOI: 10.1016/j.ijrobp.2009.06.092. View

15.

Andolino D, Johnson C, Maluccio M, Kwo P, Tector A, Zook J . Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81(4):e447-53. DOI: 10.1016/j.ijrobp.2011.04.011. View

16.

Osmundson E, Wu Y, Luxton G, Bazan J, Koong A, Chang D . Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract. Int J Radiat Oncol Biol Phys. 2015; 91(5):986-94. DOI: 10.1016/j.ijrobp.2014.11.028. View

17.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

18.

Jung J, Yoon S, Kim S, Cho B, Park J, Kim S . Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol. 2013; 8:249. PMC: 3816573. DOI: 10.1186/1748-717X-8-249. View

19.

Liaw Y, Sung J, Chow W, Farrell G, Lee C, Yuen H . Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351(15):1521-31. DOI: 10.1056/NEJMoa033364. View

20.

Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y . Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatol Res. 2014; 45(5):540-7. DOI: 10.1111/hepr.12383. View